Skip to search formSkip to main contentSkip to account menu

NXL 104

Known as: NXL-104, NXL104 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The fast and constant development of drug-resistant bacteria represents a serious medical emergence. To overcome this problem… 
2012
2012
• Among 337 Enterobacter spp. strains, 97.3% were inhibited by ceftarolineavibactam at ≤0.5 mg/L. Meropenem (MIC 90, ≤0.06 mg/L… 
2011
2011
When used with ceftazidime or other β-lactam antibiotics, NXL104, a potent inhibitor of β-lactamase enzymes, becomes a powerful… 
2011
2011
E. coli (934) 58.0 88.7 97.2 99.9 100.0 – – – ESBL-phenotype (245) 29.0 69.4 91.0 99.6 100.0 – – – Klebsiella spp. (1003) 36.3 70… 
2010
2010
The presence of multiple β-lactamases in a single cephalosporin-resistant isolate has been recognized as an alarming fact since… 
2009
2009
Background: Ceftaroline (CPT), a broad-spectrum cephalosporin with gram-positive activity (including anti-MRSA), was tested in…